tradingkey.logo
tradingkey.logo
Suchen

Veracyte Inc

VCYT
Zur Watchlist hinzufügen
57.080USD
-2.770-4.63%
Handelsschluss 07/02, 13:00ETKurse um 15 Minuten verzögert
4.53BMarktkapitalisierung
51.19KGV TTM

mehr Informationen über Veracyte Inc Unternehmen

Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.

Veracyte Inc Informationen

BörsenkürzelVCYT
Name des UnternehmensVeracyte Inc
IPO-datumOct 30, 2013
CEOStapley (Marc A)
Anzahl der mitarbeiter824
WertpapierartOrdinary Share
GeschäftsjahresendeOct 30
Addresse6000 Shoreline Court, Suite 300
StadtSOUTH SAN FRANCISCO
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl94080
Telefon16502436300
Websitehttps://www.veracyte.com/
BörsenkürzelVCYT
IPO-datumOct 30, 2013
CEOStapley (Marc A)

Führungskräfte von Veracyte Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Chief Executive Officer, Director
Chief Executive Officer, Director
142.40K
-6.33%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
48.40K
+10.89%
Dr. Eliav Barr, M.D.
Dr. Eliav Barr, M.D.
Independent Director
Independent Director
47.14K
+11.18%
Ms. Muna Bhanji
Ms. Muna Bhanji
Independent Director
Independent Director
35.26K
+14.95%
Dr. Phillip G. (Phil) Febbo, M.D.
Dr. Phillip G. (Phil) Febbo, M.D.
Chief Scientific Officer, Chief Medical Officer
Chief Scientific Officer, Chief Medical Officer
28.33K
-13.16%
Mr. Evan Jones
Mr. Evan Jones
Independent Director
Independent Director
25.31K
+20.83%
Ms. Rebecca Chambers
Ms. Rebecca Chambers
Chief Financial Officer
Chief Financial Officer
24.86K
-29.18%
Mr. Jens Holstein
Mr. Jens Holstein
Independent Director
Independent Director
23.15K
+22.77%
Mr. John Leite, Ph.D.
Mr. John Leite, Ph.D.
Global Chief Commercial Officer
Global Chief Commercial Officer
13.76K
-29.49%
Ms. Karin Eastham, CPA
Ms. Karin Eastham, CPA
Independent Director
Independent Director
5.78K
+26.71%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Chief Executive Officer, Director
Chief Executive Officer, Director
142.40K
-6.33%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
48.40K
+10.89%
Dr. Eliav Barr, M.D.
Dr. Eliav Barr, M.D.
Independent Director
Independent Director
47.14K
+11.18%
Ms. Muna Bhanji
Ms. Muna Bhanji
Independent Director
Independent Director
35.26K
+14.95%
Dr. Phillip G. (Phil) Febbo, M.D.
Dr. Phillip G. (Phil) Febbo, M.D.
Chief Scientific Officer, Chief Medical Officer
Chief Scientific Officer, Chief Medical Officer
28.33K
-13.16%
Mr. Evan Jones
Mr. Evan Jones
Independent Director
Independent Director
25.31K
+20.83%

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von Veracyte Inc?

Die fünf größten Anteilseigner von Veracyte Inc sind: Mr. Marc A. Stapley

Wie viele Institutionen halten Anteile an Veracyte Inc (VCYT)?

Mit Stand vom 2026Q1 halten 683 Institutionen Anteile an Veracyte Inc, mit einem Gesamtmarktwert von etwa 96.10M, was 120.44% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -1894546.00 gestiegen.